Zura Bio Ltd
ZURA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZURA
Zura Bio Ltd is a clinical-stage biotechnology company developing tibulizumab, a bispecific antibody targeting autoimmune and inflammatory diseases, with no approved products or revenue to date.
Key risk: No revenue or approved products
BioSniper Score
Based on 5 of 6 signals
Market Cap
$548.1M
Cash Runway
—
Lead Asset
crebankitug (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials · 1 catalyst for Zura Bio Ltd.
Zura Bio Ltd is a clinical-stage biotechnology company developing tibulizumab, a bispecific antibody targeting autoimmune and inflammatory diseases, with no approved products or revenue to date.
- Zura Bio has no approved products and has not generated any revenue from commercial sales [sec_mda · as of 2026-08-11].
- Cash and cash equivalents were $0.2M as of June 30, 2026, with a net loss of $26.3M for the six months ended June 30, 2026 [sec].
- The company expects existing cash to fund operations through at least the end of 2028, based on current business plans [sec_mda · as of 2026-08-11].
- Tibulizumab is in Phase 2 trials for autoimmune and inflammatory diseases, with topline data expected by the end of 2026 [catalyst].
- Zura Bio is obligated to pay milestone payments and royalties to Pfizer and Lilly under licensing agreements [sec_mda · as of 2026-08-11].
What works
- Zura Bio has a clear near-term catalyst with the expected Phase 2 topline readout for tibulizumab by the end of 2026 [catalyst].
- The company believes its existing cash will fund operations through at least the end of 2028, providing a runway for key development milestones [sec_mda · as of 2026-08-11].
What to weigh
- Zura Bio has no approved products or revenue and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-08-11].
- Cash and cash equivalents were only $0.2M as of June 30, 2026, indicating a need for additional financing to sustain operations beyond the current runway [sec].
- The company faces substantial milestone payment obligations to Pfizer and Lilly, which may become due before any product revenue is generated [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Zura Bio has no approved products and no revenue.
“Since our inception, we have not reached successful commercialization of our product candidates or generated any revenue”
SEC MD&A · August 11, 2026
Cash runway is expected through at least the end of 2028.
“we believe that our existing cash and cash equivalents should be sufficient to fund our operating expenses and capital requirements through at least the end of 2028”
SEC MD&A · August 11, 2026
Tibulizumab Phase 2 topline data expected by end of 2026.
“Phase2_Topline: Phase 2 Readout: tibulizumab - Expected Phase 2 topline data readout for tibulizumab in autoimmune and inflammatory diseases”
Catalysts · December 31, 2026
Milestone and royalty obligations to Pfizer and Lilly.
“We will be required to pay certain of these milestone payments prior to the time at which we are able to generate sufficient revenue, if any, from commercial sales of any of our product candidates”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · tibulizumab — Phase 2 Readout: tibulizumab — Expected topline data from Phase 2 trial of tibulizumab in autoimmune and inflammatory diseases, a key value inflection point.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — Zura Bio has no commercial products and no revenue, relying entirely on future development success [sec_mda · as of 2026-08-11].
- Limited cash runway — Cash of $0.2M as of June 30, 2026, may require additional financing before the end of 2028 [sec].
- Milestone payment obligations — Multimillion-dollar milestone payments to Pfizer and Lilly are due before any product revenue, straining finances [sec_mda · as of 2026-08-11].
- Clinical development risk — Tibulizumab is in Phase 2 and may fail to meet endpoints, delaying or preventing regulatory approval [catalyst].
What to watch
- Phase 2 topline data for tibulizumab expected by end of 2026 [catalyst].
- Any additional financing or equity offerings to extend cash runway [sec_mda · as of 2026-08-11].
- Progress of ongoing Phase 2 trials for tibulizumab in autoimmune indications [catalyst].
Sources: Catalysts · SEC MD&A · Generated August 18, 2026 · How we verify sources →
Run Zura Bio Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zura Bio Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $19M · Net income -$26M
Lead: Phase 2
3 candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
89
Total value held
$296.5M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 9,067,001 | $53.9M |
| great point partners llc | 4,215,930 | $25.1M |
| braidwell lp | 3,988,989 | $23.7M |
| commodore capital lp | 3,250,000 | $19.3M |
| adage capital partners gp, l.l.c. | 2,750,000 | $16.4M |
| affinity asset advisors, llc | 2,564,303 | $15.3M |
| millennium management llc | 1,508,063 | $9.0M |
| stempoint capital lp | 1,507,040 | $9.0M |
| armistice capital, llc | 1,507,000 | $9.0M |
| cormorant asset management, lp | 1,450,000 | $8.6M |
Showing top 10 of 89 institutional holders of Zura Bio Ltd. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.9%
- Days to cover
- 11.2
- Shares short
- 6,974,577
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZURA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zura Bio Ltd?
Zura Bio Ltd is a clinical-stage biotechnology company developing tibulizumab, a bispecific antibody targeting autoimmune and inflammatory diseases, with no approved products or revenue to date.
What is Zura Bio Ltd's lead drug candidate?
Zura Bio Ltd's most advanced tracked candidate is crebankitug (Preclinical) for Autoimmune diseases where IL-7 or TSLP signaling has been implicated.
What is Zura Bio Ltd's next catalyst?
Zura Bio Ltd's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: tibulizumab" — expected December 31, 2026.
Who is the CEO of Zura Bio Ltd?
Dr. Sandeep Chidambar Kulkarni M.D. is the chief executive officer of Zura Bio Ltd (ZURA).
Where is Zura Bio Ltd headquartered?
Zura Bio Ltd (ZURA) is headquartered in Henderson, NV, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.